SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors

被引：0
|
作者：
C. Kratochwil
M. Stefanova
E. Mavriopoulou
T. Holland-Letz
A. Dimitrakopoulou-Strauss
A. Afshar-Oromieh
W. Mier
U. Haberkorn
F. L. Giesel
机构：
[1] University Hospital Heidelberg,Department of Nuclear Medicine
[2] German Cancer Research Center,Department of Biostatistics
[3] German Cancer Research Center,KKE Nuclear Medicine
来源：
Molecular Imaging and Biology | 2015年 / 17卷
关键词：
Neuroendocrine tumors; Peptide-related radionuclide therapy; [; Ga]DOTATOC; Somatostatin receptor; SUV;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：313 / 318
页数：5
相关论文
共 50 条
  • [21] Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids
    Jindal, Tarun
    Kumar, Arvind
    Venkitaraman, Balasubramanian
    Meena, Monika
    Kumar, Rakesh
    Malhotra, Arun
    Dutta, Roman
    CANCER IMAGING, 2011, 11 (01): : 70 - 75
  • [22] The Impact of 68Ga-DOTATOC PET/CT on the Multimodal Management of Patients with Neuroendocrine Tumors
    Sotiropoulos, G.
    Li, J.
    Al-Nahhas, A.
    Spalding, D.
    Tedeschi, M.
    Carroll, R. W.
    Bockisch, A.
    NEUROENDOCRINOLOGY, 2011, 94 : 45 - 45
  • [23] A Study of Radiomic Features Robustness for 68Ga-DOTATOC PET/CT in Neuroendocrine Tumors
    Liberini, V.
    Gallio, E.
    Rampado, O.
    De Santi, B.
    Dionisi, B.
    Ceci, F.
    Pilati, E.
    Finessi, M.
    Bello, M.
    Bisi, G.
    Molinari, F.
    Deandreis, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S252 - S253
  • [24] Quantitative 68Ga-DOTATOC PET in patients with neuroendocrine tumors
    Koukouraki, S.
    Dimitrakopoulou-Strauss, A.
    Georgoulias, V.
    Schuhmacher, J.
    Haberkorn, U.
    Strauss, L. G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S115 - S115
  • [25] Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors
    Opalinska, Marta
    Morawiec-Slawek, Karolina
    Kania-Kuc, Adrian
    Al Maraih, Ibraheem
    Sowa-Staszczak, Anna
    Hubalewska-Dydejczyk, Alicja
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [26] [68Ga]-Dota Peptide PET/CT in Neuroendocrine Tumors: Main Clinical Applications
    Giovannini, Elisabetta
    Giovacchini, Giampiero
    Borso, Elisa
    Lazzeri, Patrizia
    Riondato, Mattia
    Leoncini, Rossella
    Duce, Valerio
    Ciarmiello, Andrea
    CURRENT RADIOPHARMACEUTICALS, 2019, 12 (01) : 11 - 22
  • [27] Staging of neuroendocrine tumours: comparison of [68Ga]DOTATOC multiphase PET/CT and whole-body MRI
    Schraml, C.
    Schwenzer, N. F.
    Sperling, O.
    Aschoff, P.
    Lichy, M. P.
    Mueller, M.
    Brendle, C.
    Werner, M. K.
    Claussen, C. D.
    Pfannenberg, C.
    CANCER IMAGING, 2013, 13 (01): : 63 - 72
  • [28] [68Ga]-DOTATOC PET in staging of somatostatine receptor expressing tumors.
    Hofmann, M
    Boemer, AR
    Weckesser, E
    Fricke, H
    Maecke, HR
    Knapp, WH
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 31P - 31P
  • [29] Organ-specific response to [177Lu]DOTATATE peptide receptor radionuclide therapy (PRRT) assessed by sequential [68Ga]DOTATOC PET/CT in patients with metastatic small intestine neuroendocrine tumors
    Bessac, Darejan Mamulashvili
    Baltzinger, Philippe
    Poterszman, Nathan
    Van, Floriane Pham
    Collen, Cedric
    Malouf, Gabriel G.
    Ouvrard, Eric
    Kaseb, Ashjan
    Porot, Clemence
    Ben Abdelghani, Meher
    Addeo, Pietro
    Mertz, Luc
    Goichot, Bernard
    Imperiale, Alessio
    ENDOCRINE, 2025, 87 (03) : 1333 - 1341
  • [30] Optimised target volume definition for the fractionated stereotactic radiotherapy of intracranial meningiomas by means of correlation of CT, MRT and [68Ga]-DOTATOC-PET
    Milker-Zabel, S.
    Zabel-du Bois, A.
    Henze, M.
    Huber, P.
    Schulz-Ertner, D.
    Hoess, A.
    Haberkorn, U.
    Debus, J.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 : 56 - 56
12345